Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers April 23, 2017
Pharmacy Choice - News - Generic Drugs - April 23, 2017

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 61     Next >>     Go To Page:

4/23/17 - CHMP Recommends Approval Of Sandoz Biosimilar Rituximab And Etanercept In Europe
BASEL- Sandoz, a Novartis division, announced that the Committee for Medicinal Products for Human Use has recommended approval of both Sandoz' biosimilar rituximab and biosimilar etanercept in Europe for the same indications as their respective reference medicines. Subject to EC approval, Sandoz market leadership position extended as the only compa
4/23/17 - Dr. Reddy's Lab launches Progesterone capsules in the U.S. market [India Infoline News Service]
Reddy s Laboratories Ltd., announced on April 21, 2017 that it has launched Progesterone Capsules, 100 mg and 200 mg in U.S. market Dr. Reddy s Laboratories Ltd. announced on April 21, 2017, that it has launched Progesterone Capsules, 100 mg and 200 mg, a therapeutic equivalent generic version of Prometrium* capsules in the United States mark
4/22/17 - ICYMI: Sen. Brown 'Leading Charge' to Bring Down Drug Prices
In case you missed it, the Huffington Post today released a story highlighting U.S. Sen. In March, Brown introduced sweeping prescription drug legislation the Huffington Post notes, "combines every policy idea drug lobbyists hate." The legislation follows specific steps Brown outlined to Trump in a December 2016 letter outlining specific steps his.
4/22/17 - Japan`s Sawai Pharma to buy US generics maker [Tehran Times (Iran)]
Sawai Pharmaceutical will buy the generics business of U.S. drugmaker Upsher-Smith Laboratories for $1.05 billion, the Japanese company said Thursday, eager to make up for lost time after its first push into the American market stalled. The company chose Upsher-Smith "because of its nearly 100- year history, as well as its high name recognition in
4/22/17 - Sandoz proposed biosimilars rituximab and etanercept recommended for approval in Europe* [Algeria Press Service]
-Sandoz receives positive CHMP opinions for biosimilars rituximab and etanercept to treat immunological diseases. Holzkirchen, April 21, 2017- Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, announced today that the Committee for Medicinal Products for Human Use has adopted positive opinions, separately recommending t
4/21/17 - $3 million awarded to widow who sued pharmaceutical firm over husband's suicide [Chicago Tribune]
April 21 A Glencoe woman hugged her attorneys after a jury in Chicago awarded her $3 million Thursday in a lawsuit against a pharmaceutical company that she blamed for her husband's suicide. Wendy Dolin's husband, Stewart, stepped in front of a CTA Blue Line train in the Loop on July 15, 2010. Stewart Dolin was a corporate attorney and a partner
4/21/17 - $3M award in suit against drug company over man's suicide
CHICAGO A suburban Chicago woman has been awarded $3 million in a lawsuit against a pharmaceutical company she blamed for her husband's suicide.
4/21/17 - Alvogen to Market Regenerative Fish Skin in Korea, Taiwan and Thailand
Global pharmaceutical company Alvogen will market the Kerecis fish-skin-based diabetic wound treatment products in Asia starting in Korea, Taiwan and Thailand. The Kerecis products will support Alvogen's hospital portfolio. "More than 60 percent of the diabetics in the world live in Asia," said G. Fertram Sigurjonsson, Chairman and CEO of Kerecis.
4/21/17 - Brazil Generic Drug Market: Industry Trends, Share, Size, Growth, Forecast and Opportunity 2017-2022
Dublin- Research and Markets has announced the addition of the "Brazil Generic Drug Market: Industry Trends, Share, Size, Growth, Forecast and Opportunity 2017-2022" report to their offering. The report entitled Brazil Generic Drug Market: Industry Trends, Share, Size, Growth, Forecast and Opportunity 2017-2022 represents an in-depth analysis on th
4/21/17 - Brazil Generic Drug Market: Industry Trends, Share, Size, Growth, Forecast and Opportunity 2017-2022 - Research and Markets
Research and Markets has announced the addition of the " Brazil Generic Drug Market: Industry Trends, Share, Size, Growth, Forecast and Opportunity 2017-2022" report to their offering. The report entitled Brazil Generic Drug Market: Industry Trends, Share, Size, Growth, Forecast and Opportunity 2017-2022 represents an in-depth analysis on the histo
4/21/17 - Celgene Notified of ANDA Filing for POMALYST
By a News Reporter-Staff News Editor at Drug Week Celgene Corporation has received a Paragraph IV Notice Letter advising that Teva Pharmaceuticals USA, Inc. submitted an Abbreviated New Drug Application to the U.S. Food and Drug Administration seeking authorization from the FDA to manufacture and market a generic version of POMALYST 1 mg, 2 mg
4/21/17 - Dr. Reddy's Laboratories Announces the Launch of Progesterone Capsules in the U.S. Market
HYDERABAD, India& PRINCETON, N.J. Dr. Reddy s Laboratories Ltd announced today that it has launched Progesterone Capsules, 100 mg and 200 mg, a therapeutic equivalent generic version of Prometrium Capsules in the United States market, approved by the U.S. Food and Drug Administration. The Prometrium brand and generic had U.S. sales of
4/21/17 - Evenstad family sells Upsher-Smith Labs generics business to Japanese firm for $1 billion [Star Tribune (Minneapolis)]
April 21 Maple Grove- based Upsher-Smith Laboratories has agreed to sell its generic pharmaceuticals business for $1.05 billion to Sawai Pharmaceutical Co. of Japan. Upsher-Smith is owned by the Evenstad family through its privately held holding company Acova Inc. Mark Evenstad is CEO of Upsher-Smith and his father, Ken, is company chairman.
4/21/17 - FDA approves 2nd near-copy of Remicade for immune disorders
The U.S. Food and Drug Administration approved Renflexis, developed by Samsung Bioepis Co. of South Korea. Its U.S. partner, Merck& Co. of Kenilworth, New Jersey, will market Renflexis. The first biosimilar for Remicade, Inflectra from New York- based Pfizer Inc., went on sale in November at a 15 percent discount.
4/21/17 - Global Biologics and Biosimilars Market 2017 Competitive Situation and Trends to 2022
The Global Biologics and Biosimilars Industry report provides key information including invaluable facts, figures& the latest developments across the globe.. DALLAS, TEXAS, UNITED STATES, April 21, 2017/ EINPresswire.com/ In this report, the Global Biologics and Biosimilars Market is valued at USD XX million in 2016 and is expected to reach USD X
4/21/17 - Impax to Present Data on Rytary (Carbidopa and Levodopa) Extended-Release Capsules, Zomig (Zolmitriptan) Nasal Spray and Investigational Drug IPX203 at the 2017 American Academy of Neurology Annual Meeting
Impax Laboratories, Inc. today announced that it will be presenting data from the Company's neurology clinical development programs, including data from a single-dose Phase 2 a study on investigational drug IPX203 in patients with advanced Parkinson's Disease in the Emerging Science Program at the American Academy of Neurology conference in Bosto
4/21/17 - Japan`s Sawai Pharma to buy US generics firm Upsher-Smith for $1.05 bn [Syrian Arab News Agency]
Japanese generic drug maker Sawai Pharmaceutical Co Ltd is making its first overseas acquisition by offering to buy its US peer Upsher-Smith Laboratories Inc from its parent, Acova Inc., for $1.05 billion. Upsher-Smith is a privately-held company, owned by the Evenstad family through their company Acova and is run by CEO, Mark Evenstad and his fath
4/21/17 - Japan`s Sawai Pharmaceutical to Acquire the Generics Business of U.S. Upsher-Smith Laboratories [Tehran Times (Iran)]
Sawai Pharmaceutical Co. Ltd., a leading Japanese generic pharmaceuticals manufacturer, and Upsher-Smith Laboratories, Inc.,, an established generics manufacturer based in Minnesota, U.S., today announced the signing of an agreement for Sawai to purchase the generic pharmaceuticals business of Upsher-Smith, from its parent, ACOVA, Inc.,.
4/21/17 - Mylan releases generic version of Trilafon
Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for this product, which is used in the treatment of schizophrenia and for the control of severe nausea and vomiting in adults.Perphenazine tablets had U.S. sales of approximately $41 million for the 12 months ending Feb. 28, according t
4/21/17 - New Findings from National School of Public Health in the Area of Health and Society Reported (Why do generic drugs fail to achieve an adequate...
New Findings from National School of Public Health in the Area of Health and Society Reported. According to news reporting from Athens, Greece, by NewsRx journalists, research stated, "Since 2010, the memoranda of understanding were implemented in Greece as a measure of fiscal adjustment. Yet, generics' penetration in Greece remained among the lowe
4/21/17 - Sandoz proposed biosimilars rituximab and etanercept recommended for approval in Europe*
Novartis International AG/ Sandoz proposed biosimilars rituximab and etanercept recommended for approval in Europe*. Biosimilar rituximab also recommended to treat blood cancers* Comprehensive data packages, confirming Sandoz biosimilars rituximab and etanercept match their respective reference medicines, were the basis for CHMP decisions* Subject.
4/21/17 - Teligent, Inc. To Hold Conference Call For 1st Quarter 2017 Results
Teligent, Inc., a New Jersey- based specialty generic pharmaceutical company, announced the Company will hold a conference call at 4:15 pm ET on Tuesday, May 2, 2017 to discuss the 1st quarter 2017 results. The Company invites you to listen to the call by dialing 1-888-346-3479. International participants should call 1-412-902-4260. Canadian part
4/21/17 - Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) Asthma Inhaler To Compete With GlaxoSmithKline plc (ADR) (NYSE:GSK) Advair
The launch of an asthma inhaler by Teva Pharmaceutical Industries Ltd (ADR)(NYSE:TEVA) is likely to put GlaxoSmithKline plc (ADR)(NYSE:GSK) best-selling Advair in a tight spot. AirDuo RespiClick from Teva is an inhalation powder. While it may not be a true generic of Advair it has the endorsement of the treatment of asthma in patients aged [?] Th
4/21/17 - VANC Pharmaceuticals Appointment of Mr. Alan Arnstein to its Board of Directors [Palestine News Agency (WAFA)]
Mr. Arnstein previously worked for the Katz Group Canada where he oversaw the development of the Medicine Shoppe from 28 stores to 175 stores before the successful sale to McKesson Canada. Mr. Arnstein also was very involved in expanding the Rexall pharmacy brand across Canada including responsibility for acquiring and consolidating independent...
4/21/17 - Widow who sued pharmaceutical firm over husband's suicide awarded $3M [Chicago Tribune]
April 21 A Glencoe woman hugged her attorneys after a jury in Chicago awarded her $3 million Thursday in a lawsuit against a pharmaceutical company that she blamed for her husband's suicide. Wendy Dolin's husband, Stewart, stepped in front of a CTA Blue Line train in the Loop on July 15, 2010. Stewart Dolin was a corporate attorney and a partner
Articles(s): 1 - 25 of 61     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415